Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
98,493,468
-
Shares change
-
-7,610,979
-
Total reported value, excl. options
-
$283,669,170
-
Value change
-
-$32,502,791
-
Put/Call ratio
-
173%
-
Number of buys
-
55
-
Number of sells
-
-55
-
Price
-
$2.88
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2021
147 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q3 2021.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98,493,468 shares
of 236,234,693 outstanding shares and own 41.69% of the company stock.
Largest 10 shareholders include STATE STREET CORP (15,856,428 shares), BlackRock Inc. (14,051,942 shares), VANGUARD GROUP INC (12,411,243 shares), MARSHALL WACE, LLP (6,968,811 shares), Nantahala Capital Management, LLC (4,978,195 shares), SATTER MANAGEMENT CO., L.P. (4,652,561 shares), JPMORGAN CHASE & CO (4,565,548 shares), GEODE CAPITAL MANAGEMENT, LLC (3,229,943 shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2,662,045 shares), and Woodline Partners LP (2,323,517 shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.